XTX Topco Ltd Takes Position in STAAR Surgical (NASDAQ:STAA)

XTX Topco Ltd bought a new position in shares of STAAR Surgical (NASDAQ:STAA) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 13,668 shares of the medical instruments supplier’s stock, valued at approximately $508,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Arcadia Investment Management Corp MI bought a new position in shares of STAAR Surgical in the third quarter worth $37,000. Quarry LP purchased a new position in STAAR Surgical during the third quarter worth about $50,000. Quest Partners LLC bought a new position in STAAR Surgical in the 3rd quarter worth about $128,000. Canada Pension Plan Investment Board bought a new position in STAAR Surgical in the 2nd quarter worth about $129,000. Finally, Van ECK Associates Corp raised its holdings in shares of STAAR Surgical by 12.7% in the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after acquiring an additional 393 shares in the last quarter. 96.70% of the stock is currently owned by hedge funds and other institutional investors.

STAAR Surgical Stock Performance

STAA stock opened at $24.86 on Friday. STAAR Surgical has a one year low of $24.21 and a one year high of $52.68. The company has a market capitalization of $1.23 billion, a PE ratio of 56.50 and a beta of 0.59. The company’s 50 day moving average price is $28.91 and its two-hundred day moving average price is $35.01.

Wall Street Analysts Forecast Growth

STAA has been the topic of several research analyst reports. Stifel Nicolaus decreased their price objective on shares of STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Monday, August 26th. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a report on Thursday, October 31st. Stephens upgraded shares of STAAR Surgical to a “hold” rating in a research report on Monday, December 2nd. Finally, Canaccord Genuity Group cut their target price on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a research report on Monday, December 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, STAAR Surgical currently has a consensus rating of “Hold” and an average price target of $42.83.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.